Energy Impact Partners Backs Greentech Zolar, Increases Series B to 35 Million
16.3.2021 17:15:00 EET | Business Wire | Press release
The Berlin-based Greentech start-up Zolar receives a new investment and adds 10 million euro to the ongoing Series B funding round, raising the total investment of this series to 35 million euro. The new investment is lead by Energy Impact Partners, the biggest investor in the energy sector with offices in the USA and Europe headed by its managing partner Matthias Dill. Existing investors continue to support Zolar in the Series B. With the additional resources, the start-up sets the course for the expansion as a next generation green energy company, focusing on sustainable energy production and integral use of solar energy in private households. Zolar as a consumer brand, is placing customers at the center of energy production, and is driven by its mission of climate protection as a top business priority.
Energy provider of the future– The Next Generation Green Energy Company
The start-up defines five quality criteria, which represent the next generation of energy companies: decentralized renewable energy systems, green and affordable energy, customer centricity, significant reduction in customers’ carbon footprint, with an ultimate goal of carbon neutrality, as well as electrification and smart energy management. By installing a solar system on their own roof, customers are enabled to secure and allocate the main energy requirements of the household. Essential to this is the combination of electric mobility and solar energy, as well as the usage of self-generated power stored in residential batteries. The need for green and sustainably produced energy is also evident, due to rapidly increasing demands from customers. Zolar responds to this trend and offers homeowners an alternative to traditional energy companies, who continue to rely on fossil fuels.
“We find ourselves at the dawn of the solar age” explains Alex Melzer, CEO and co-founder of Zolar. “The solar sector proved to be very stable during the Covid-19 pandemic. In the past year, we have been able to grow our revenue significantly, and in 2021, we are targeting to triple installations across Germany. With the fresh 10 million, we are taking the company to the next level and The investment of Energy Impact Partners shows that investors recognise the relevance of regenerative energy. In doing so, they support us to grow quicker, accelerate revenue growth while at the same time having a positive impact on climate protection. Because ultimately what drives us all, is a livable future for all humans”, continued Melzer.
Private households become energy suppliers
In order for every household to become its own energy supplier, Zolar relies on technological platform solutions across the whole value chain. With full service digital concept, beginning with the Zolar Online Configurator, from a holistic customer journey to roof installation via the partner platform Zolar Project Center. The company intends to establish itself as a leading customer brand in the energy sector and is planning an expansion of the core business. In keeping with the requirement of an electrified household, the product portfolio will facilitate an integration of energy production, power storage and mobility.
“Zolar is one of the fastest growing energy start-ups in Germany”, added Matthias Dill, Managing Partner of Energy Impact Partners. “At Energy Impact Partners we closely monitor the transformation of the energy sector and with this investment we intend to provide ongoing support for Zolar’s goal – to become the energy provider of the future. The combination of technological state-of-the-art platforms, customer success and climate protection is a clear formula for success for us” continued Dill.
About Zolar
The Greentech start-up Zolar offers fixed-priced photovoltaic systems, which home owners can plan, compare and commission online, according to their needs. With the help of the in-house developed Zolar Online Configurator, homeowners have the possibility to adjust the components of their PV system according to their wishes, and along with this, receive an individual consultation from solar experts. Zolar’s wide network of local partner businesses carries out the installation on-site. The Berlin start-up employs around 150 employees across Germany and pursues the vision, to install solar panelling on every roof in the world, granting private households greater independence from energy supply systems. The gearing of energy production, energy storage and mobility enables the customer to design an electrified and smart household. As a next green energy company, Zolar empowers its customers to become energy suppliers within its own four walls, to neutralize their carbon footprint and to make an impact towards climate protection.
More information at: http://www.zolar.de
About Energy Impact Partners
Energy Impact Partners (EIP) is a global investment platform leading the transition to a sustainable energy future. EIP brings together entrepreneurs and the world's most forward-looking energy and industrial companies to advance innovation. With over $1.5 billion in assets under management, EIP invests globally across venture, growth, credit and infrastructure – and has a team of more than 45 professionals based in its offices in New York, San Francisco, Palm Beach, London, and Cologne.
For more information on EIP, please visit: www.energyimpactpartners.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210316005732/en/
Contact information
Press Contact
Lina Wölm
VP Marketing & Communications
Phone: +49 30 398 218 443
Email: lina.woelm@zolar.de
Website: http://www.zolar.de
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
